Maravai Lifesciences Holdings (MRVI) Other Non-Current Assets (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Other Non-Current Assets of $40.2 million for Q1 2026, down 30.13% year-over-year from $57.6 million in Q1 2025, and down 3.92% quarter-over-quarter from $41.9 million in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $40.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 30.13% year-over-year to $40.2 million; the TTM figure through Mar 2026 stood at $40.2 million (down 30.13% YoY), while the FY2025 annual figure was $41.9 million, down 29.96% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $40.2 million, down from $41.9 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $127.0 million in Q1 2023, with the low at $40.2 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $64.2 million (2022), against an average of $71.9 million.
- Peak annual rise in Other Non-Current Assets reached 2028.57% in 2022, while the deepest fall reached 42.08% in 2022.
- Maravai Lifesciences Holdings' Other Non-Current Assets stood at $115.6 million in 2022, then plunged by 32.85% to $77.6 million in 2023, then slipped by 22.97% to $59.8 million in 2024, then fell by 29.96% to $41.9 million in 2025, then dropped by 3.92% to $40.2 million in 2026.
- Business Quant data shows MRVI's Other Non-Current Assets at $40.2 million in Q1 2026, $41.9 million in Q4 2025, and $49.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 37.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.87 Mn |
| Mar 31, 2026 | 40.24 Mn |
| Dec 31, 2025 | 41.88 Mn |
| Sep 30, 2025 | 49.40 Mn |
| Jun 30, 2025 | 51.98 Mn |
| Mar 31, 2025 | 57.58 Mn |
| Dec 31, 2024 | 59.79 Mn |
| Sep 30, 2024 | 60.91 Mn |
| Jun 30, 2024 | 63.47 Mn |
| Mar 31, 2024 | 74.98 Mn |
| Dec 31, 2023 | 77.62 Mn |
| Sep 30, 2023 | 85.58 Mn |
| Jun 30, 2023 | 92.74 Mn |
| Mar 31, 2023 | 127.04 Mn |
| Dec 31, 2022 | 115.59 Mn |
| Sep 30, 2022 | 87.40 Mn |
| Jun 30, 2022 | 72.42 Mn |
| Mar 31, 2022 | 64.24 Mn |
| Dec 31, 2021 | 53.45 Mn |
| Sep 30, 2021 | 4.11 Mn |